Name (Synonyms) | Correlation | |
---|---|---|
drug365 | Hydroxychloroquine + azithromycin + / - tocilizumab Wiki | 1.00 |
drug500 | Mefloquine + azithromycin + / - tocilizumab Wiki | 1.00 |
drug360 | Hydroxychloroquine Wiki | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D011024 | Pneumonia, Viral NIH | 0.17 |
D011014 | Pneumonia NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Description: The number of patients with development of respiratory failure requiring transfer to the ICU.
Measure: 1st primary endpoint for group 1 Time: up to 3 monthsDescription: The period of clinical recovery.
Measure: 2nd primary endpoint for group 1 Time: through study completion, an average of 3 monthsDescription: The period of clinical recovery.
Measure: 1st primary endpoint for group 2 Time: through study completion, an average of 3 monthsDescription: Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)
Measure: 2nd primary endpoint for group 2 Time: through study completion, an average of 3 monthsDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 1 Time: on days 5, 10 and 90Description: Frequency of clinical recovery on day 10 from the start of therapy
Measure: 2nd secondary endpoint for group 1 Time: on day 10Description: The retention time of the reaction temperature from the start of treatment.
Measure: 3d secondary endpoint for group 1 Time: up to 3 monthsDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 1 Time: up to 3 monthsDescription: Respiratory index.
Measure: 5th secondary endpoint for group 1 Time: up to 3 monthsDescription: Frequency of adverse events and serious adverse events
Measure: 6th secondary endpoint for group 1 Time: through study completion, an average of 3 monthsDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 2 Time: on days 5, 10 and 90Description: Respiratory index.
Measure: 2nd secondary endpoint for group 2 Time: up to 3 monthsDescription: The retention time of the reaction temperature from the start of treatment.
Measure: 3d secondary endpoint for group 2 Time: up to 3 monthsDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 2 Time: up to 3 monthsDescription: Number of patients required transition to alternative therapy schedule
Measure: 5th secondary endpoint for group 2 Time: through study completion, an average of 3 monthsDescription: Frequency of adverse events and serious adverse events
Measure: 6th secondary endpoint for group 2 Time: through study completion, an average of 3 months